Literature DB >> 12874458

Use of the tetracycline system for inducible protein synthesis in the kidney.

Anna Rachel Gallagher1, Kai Schönig, Nelson Brown, Hermann Bujard, Ralph Witzgall.   

Abstract

The great advantage of the tetracycline-inducible system lies in its ability to address a large variety of biological questions in a time-dependent and tissue-specific manner. This study describes a transgenic mouse line, rTA(LAP)-1, which produces the reverse tetracycline transactivator under control of the liver activator protein (LAP) promoter. Two reporter lines with luciferase and LacZ reporter genes were used to demonstrate predominant expression in the kidney and liver when doxycycline was added to the drinking water. In the kidney, transgene expression was found primarily in cortical proximal tubules. No luciferase and beta-galactosidase activity was detected in mice without doxycycline in the drinking water, which attests to the tight control of this system. One of the advantages of the tet system lies in its reversibility, and indeed, a virtually complete remission of transgene activity in both the kidney and liver was observed when doxycycline was withdrawn. Also examined was transactivator activity during development by exposing the mothers producing the reverse transactivator to doxycycline before mating. Transgene activity was detected in newborn kidneys and liver, indicating that sufficient amounts of doxycycline had crossed the placental barrier. During nephron development, the LAP promoter appeared to be only active in the more mature proximal tubules. Finally, the rTA(LAP)-1 line was used to inducibly express the human PKD2 cDNA in proximal tubules of transgenic mice, but no cystic changes were detected, even after 6 mo of induction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874458     DOI: 10.1097/01.asn.0000079615.38843.4a

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin.

Authors:  Zetang Wu; Marina Mata; David J Fink
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Development of single-vector Tet-on inducible systems with high sensitivity to doxycycline.

Authors:  Jiun-Shuan Chao; Chun-Chieh Chao; Chu-Li Chang; Yi-Rong Chiu; Chiun-Jye Yuan
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

3.  Development of a BAC vector for integration-independent and tight regulation of transgenes in rodents via the Tet system.

Authors:  Kai Schönig; David Kentner; Manfred Gossen; Tina Baldinger; Jun Miao; Katrin Welzel; Andreas Vente; Dusan Bartsch; Hermann Bujard
Journal:  Transgenic Res       Date:  2010-07-18       Impact factor: 2.788

4.  LMX1B is essential for the maintenance of differentiated podocytes in adult kidneys.

Authors:  Tillmann Burghardt; Jürgen Kastner; Hani Suleiman; Eric Rivera-Milla; Natalya Stepanova; Claudio Lottaz; Marion Kubitza; Carsten A Böger; Sarah Schmidt; Mathias Gorski; Uwe de Vries; Helga Schmidt; Irmgard Hertting; Jeffrey Kopp; Anne Rascle; Markus Moser; Iris M Heid; Richard Warth; Rainer Spang; Joachim Wegener; Claudia T Mierke; Christoph Englert; Ralph Witzgall
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

5.  Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo.

Authors:  John Wilkinson; Xiumin Di; Kai Schönig; Joan L Buss; Nancy D Kock; J Mark Cline; Thomas L Saunders; Hermann Bujard; Suzy V Torti; Frank M Torti
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

6.  Doxycycline accelerates renal cyst growth and fibrosis in the pcy/pcy mouse model of type 3 nephronophthisis, a form of recessive polycystic kidney disease.

Authors:  Larissa Osten; Marion Kubitza; Anna Rachel Gallagher; Jürgen Kastner; Heike Olbrich; Uwe de Vries; Frieder Kees; Brigitte Lelongt; Stefan Somlo; Heymut Omran; Ralph Witzgall
Journal:  Histochem Cell Biol       Date:  2009-04-21       Impact factor: 4.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.